About the program

The discovery of oncogenic driver alterations and the development of targeted therapies have revolutionized cancer treatment. Precision medicine, or the utilization of targeted therapies in select subgroups with specific molecular alterations, means we can tailor treatments to individual patients that are more likely to show benefit. This is becoming the gold standard in many facets of medical care.

Several oncogenic driver alterations are now used as standard in the selection of treatment regimens in non-small cell lung cancer (NSCLC), such as EGFR, ALK, ROS1, BRAF, HER2 and NTRK, with more being discovered.

This expert-led program will help individualize management of NSCLC by providing education on biomarker testing for NTRK fusions and HER2 mutations, current evidence-based guidelines, and new and emerging targeted therapies.

Learn more about the educational activities below.